- Home
- GAB vs BEAM Comparison
GAB vs BEAM Comparison
Compare GAB & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAB
- BEAM
- Stock Information
- Founded
- GAB 1986
- BEAM 2017
- Country
- GAB United States
- BEAM United States
- Employees
- GAB N/A
- BEAM N/A
- Industry
- GAB Investment Managers
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GAB Finance
- BEAM Health Care
- Exchange
- GAB Nasdaq
- BEAM Nasdaq
- Market Cap
- GAB 1.8B
- BEAM 1.9B
- IPO Year
- GAB N/A
- BEAM 2020
- Fundamental
- Price
- GAB $5.51
- BEAM $25.75
- Analyst Decision
- GAB
- BEAM Buy
- Analyst Count
- GAB 0
- BEAM 10
- Target Price
- GAB N/A
- BEAM $48.75
- AVG Volume (30 Days)
- GAB 667.8K
- BEAM 1.1M
- Earning Date
- GAB 01-01-0001
- BEAM 02-25-2025
- Dividend Yield
- GAB 10.91%
- BEAM N/A
- EPS Growth
- GAB N/A
- BEAM N/A
- EPS
- GAB N/A
- BEAM N/A
- Revenue
- GAB N/A
- BEAM $349,643,000.00
- Revenue This Year
- GAB N/A
- BEAM N/A
- Revenue Next Year
- GAB N/A
- BEAM $14.08
- P/E Ratio
- GAB N/A
- BEAM N/A
- Revenue Growth
- GAB N/A
- BEAM 328.73
- 52 Week Low
- GAB $4.56
- BEAM $20.84
- 52 Week High
- GAB $5.88
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- GAB 48.88
- BEAM 49.43
- Support Level
- GAB $5.43
- BEAM $24.33
- Resistance Level
- GAB $5.61
- BEAM $27.97
- Average True Range (ATR)
- GAB 0.07
- BEAM 1.55
- MACD
- GAB 0.00
- BEAM 0.13
- Stochastic Oscillator
- GAB 37.50
- BEAM 59.41
About GAB Gabelli Equity Trust Inc. (The)
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.